Hyun-Jung Cho

Structural basis and preclinical efficacy of MG1124, a novel CEACAM1-targeting antibody synergizing with PD-1 blockade.

CEACAM1 homodimerization mediates tumor immune evasion, presenting a compelling target to overcome resistance to PD-1 blockade. However, defining a precise structural and pharmacological blueprint for CEACAM1 targeting has remained challenging. Here, we report the discovery and comprehensive preclinical characterizatio...